Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2019-03-18 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
西南证券股份有限公司关于公司2018年度保荐工作报告
Regulatory Filings Classification · 95% confidence The document is titled as a '2018年度保荐工作报告' which translates to '2018 Annual Sponsorship Work Report' by Southwest Securities Co., Ltd. regarding Pu Luo Pharmaceutical Co., Ltd. The content details the sponsorship work overview, issues found, measures taken, company and shareholder commitments, and other related matters. It is a detailed report on the sponsorship activities and compliance related to the company for the year 2018. It is not an annual report (10-K), audit report, or earnings release. It is also not a simple announcement or certification but a substantive report on sponsorship work. This type of document aligns with the category of Regulatory Filings (RNS) as it is a regulatory compliance report related to sponsorship work and does not fit other more specific categories like Annual Report or Audit Report. The document length is 2667 characters, which is substantive but not extremely long, consistent with a regulatory filing report rather than a full annual report or financial statement.
2019-03-18 Chinese
西南证券股份有限公司关于公司非公开发行股票持续督导总结报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "非公开发行股票持续督导总结报告" which translates to "Non-public Issuance of Shares Continuous Supervision Summary Report." It is issued by the sponsoring institution (西南证券股份有限公司) regarding the non-public issuance of shares by 普洛药业股份有限公司. The document details the continuous supervision work done by the sponsor during the issuance period, including due diligence, compliance with regulations, and the use of raised funds. It is a summary report related to the supervision of a capital raising event, not the capital raising announcement itself or a financial report like an annual or interim report. The document length is about 2900 characters, which is relatively short and focused on the supervision summary. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to the issuance and supervision of new shares and fundraising activities.
2019-03-18 Chinese
关于控股股东部分股份解除质押的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the release of pledged shares by a controlling shareholder. It details the number of shares released from pledge, the dates of pledge and release, and the proportion of shares involved. There is no financial report, earnings data, or management discussion. The content fits the category of shareholding or capital structure changes related to pledged shares. This matches the description of a Share Issue/Capital Change (SHA) filing, which includes announcements about share pledges and releases. The document length is short and it is not a report publication or certification. Therefore, the classification is SHA with high confidence.
2019-03-13 Chinese
独立董事关于公司2018年度日常关联交易实际情况与预计存在差异事项的专项意见
Audit Report / Information Classification · 95% confidence The document is a special opinion from the independent directors of 普洛药业股份有限公司 regarding the company's 2018 annual related party transactions actual situation versus the forecasted amounts. It references regulatory guidelines about independent directors and disclosure formats for related party transactions. The document contains detailed explanations of differences between actual and forecasted related party transactions for the fiscal year 2018, including amounts and reasons for discrepancies. It is signed by the independent directors and dated March 12, 2019. The content is focused on audit and compliance of related party transactions, not a full annual report or earnings release. It is a standalone audit-related opinion document concerning accounting and disclosure compliance, fitting the category of Audit Report / Information (AR). The document length is short (1399 characters), but it contains substantive content and is not merely an announcement or certification. Therefore, it is classified as AR with high confidence. FY 2018
2019-03-12 Chinese
关于2019年日常关联交易预计的补充更正公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the company's 2019 daily related party transactions, including supplementary corrections to previously disclosed information. It contains extensive financial data on related party transactions, comparisons of actual vs. estimated amounts for the previous year, explanations for discrepancies, and independent directors' opinions on these transactions. The document is not a full annual or interim report but a regulatory disclosure focused on related party transactions, which is typical for regulatory filings in Chinese listed companies. It does not fit the definitions of Annual Report, Interim Report, or Earnings Release. It is not a simple announcement of a report publication but contains substantive financial and operational data. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2019-03-12 Chinese
2018年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2018年度监事会工作报告" which translates to "2018 Supervisory Board Work Report". It details the supervisory board's activities, meetings, opinions on various financial reports (annual report, quarterly reports, internal control reports), and their oversight of company operations and financials during 2018. The document is a report from the supervisory board summarizing their work and findings for the year 2018. It is not the annual report itself, nor is it an announcement or certification. It is a management-related report focusing on supervisory board activities and oversight, which fits best under Management Reports (MDA). The document length is 2260 characters, which is relatively short but contains substantive content about supervisory board work and opinions on financial reports, not just an announcement or certification. Therefore, the classification is Management Reports (MDA) with high confidence.
2019-03-08 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.